Emergent may be able to resume J&J COVID-19 shot production 'within days' -CEO
May 19 (Reuters) - Emergent BioSolutions Inc (EBS.N) could resume making Johnson & Johnson's (JNJ.N) COVID-19 vaccine "within days" of getting the regulatory go-ahead, but is still fixing the problems that ruined millions of doses in March, its chief executive said on Wednesday at a U.S. House Oversight Committee hearing.
Emergent told the U.S. Food and Drug Administration in recent weeks it may take until July to correct all of the problems at its manufacturing facility, including training staff and acquiring additional refrigerators, according to a private correspondence published by the Oversight Committee on Wednesday.
"As we articulated to the FDA... there are a number of steps that we suggested be implemented," Emergent CEO Robert Kramer said during the hearing. "We are very close to completing them, and I would expect that we will be in a position to resume production within a matter of days."
The FDA halted production of J&J's vaccine at Emergent's Baltimore plant in April after an inspection flagged numerous serious quality control and sanitary issues. read more
The company contaminated millions of vaccine doses during multiple incidents in 2020 and 2021, the memo said.
Emergent shares were down 3%, while J&J shares were off slightly.
Kramer said it was his understanding that there are 100 million doses of J&J's one-shot vaccine ready for FDA review and that regulators began the review process more than a week ago.
Emergent Executive Chairman Fuad El-Hibri was repeatedly questioned at the hearing about his ties to the Trump administration. An official under former President Donald Trump who oversaw the U.S. government's vaccine deal with Emergent had previously received consulting fees from the company, the U.S. House memo said.
El-Hibri said it was "simply not true" that his relationship with Trump official Robert Kadlec influenced the U.S. government's contract award.
Kramer said at the hearing that he "can't specifically comment" on the total number of COVID-19 vaccine doses that were ruined at the Baltimore facility.
In March he said material for 15 million J&J doses was ruined. He also said "a number" of batches of AstraZeneca's (AZN.L) COVID-19 vaccine were ruined in early production ramp ups.
It is unclear whether Emergent can begin manufacturing more COVID-19 vaccine before correcting all the issues flagged by U.S. regulators.
'DESTROYING MILLIONS OF VACCINE DOSES'
Emergent had not previously disclosed a timeline for resuming vaccine production. In a late April investor call, Kramer said he is "hopeful that we can soon return to producing tens of millions of doses per month." read more
Staff working for the government's Operation Warp Speed program in June 2020 flagged "significant" personnel issues at Emergent's Maryland plant, including that "the staffing plans presented seem inadequate" to produce three products, according to a draft report cited in the memo.
The report said recent audits, including one by the FDA, "highlighted the need for extensive training of personnel."
The memo also said Emergent executives gave themselves millions of dollars in bonuses in 2020 despite knowing that their facilities were ruining batches of COVID-19 vaccines.
J&J's vaccine was contaminated with ingredients from AstraZeneca's shot, which was also being produced at the plant at the time. Production of AstraZeneca's vaccine was subsequently moved elsewhere and manufacture of J&J's vaccine was halted there after the FDA inspection.
"At the same time that the company was destroying millions of vaccine doses... its executives were cashing out," said U.S. Congresswoman Carolyn Maloney, a Democrat.
Kramer said the U.S. government contracted with Emergent in 2012 to help it prepare for public health emergencies, but failed to provide the financial support needed to boost capacity ahead of the pandemic.
U.S. government funding "persistently fell short of what was needed to reach full operating potential," Kramer said in his opening remarks to the Congressional committee.
"As a result, at the end of 2019, (the Baltimore plant) had roughly 100 employees," and was less than a year away from being charged with making millions of COVID-19 shots, the CEO said.
Our Standards: The Thomson Reuters Trust Principles.